Literature DB >> 33599348

The impact of duration of illness on treatment nonresponse and drop-out: Exploring the relevance of enduring eating disorder concept.

Fernando Fernández-Aranda1,2,3,4, Janet Treasure5, Georgios Paslakis6, Zaida Agüera1,2,3,7, Mónica Giménez1, Roser Granero3,8, Isabel Sánchez1,3, Eduardo Serrano-Troncoso9, Philip Gorwood10, Beate Herpertz-Dahlmann11, Eva-Maria Bonin12, Palmiero Monteleone13, Susana Jiménez-Murcia1,2,3,4.   

Abstract

OBJECTIVE: There are no generally accepted definitions or markers of treatment nonresponse in eating disorders (EDs). The aim of this paper was to examine how the duration of illness and other potential prognostic markers impacted on nonresponse and drop-out from treatment across different EDs subtypes.
METHODS: A total sample of 1199 consecutively treated patients with EDs, according to Diagnostic and Statistical Manual of Mental Disorders, fifth edition criteria, participated in this study. Kaplan-Meier curves were calculated for each ED diagnosis in which the probability of recovery was plotted against the duration of illness.
RESULTS: Full remission was more likely for people with binge eating disorder (BED; 47.4%) and anorexia nervosa (AN; 43.9%) compared to bulimia nervosa (BN; 25.2%) and other specified feeding and EDs (OSFED; 23.2%). The cut-off points for the duration of the illness related with high likelihoods of poor response was 6-8 years among OSFED, 12-14 years among AN and BN and 20-21 years among BED. Other variables predicting nonresponse included dysfunctional personality traits.
CONCLUSIONS: Nonresponse to treatment is associated with duration of illness which is in turn associated with poor response to previous treatment. However, there was no evidence for staging the illness using specific duration of illness criteria. Nevertheless, the shorter temporal trajectory for OSFED suggests that early interventions may be of importance for this group.
© 2020 Eating Disorders Association and John Wiley & Sons Ltd.

Entities:  

Keywords:  anorexia nervosa; binge eating disorder; bulimia nervosa; drop-out; enduring; other specified feeding and eating disorders; treatment nonresponders

Mesh:

Year:  2021        PMID: 33599348     DOI: 10.1002/erv.2822

Source DB:  PubMed          Journal:  Eur Eat Disord Rev        ISSN: 1072-4133


  5 in total

1.  How Different Are Threshold and Other Specified Feeding and Eating Disorders? Comparing Severity and Treatment Outcome.

Authors:  Samantha J Withnell; Abbigail Kinnear; Philip Masson; Lindsay P Bodell
Journal:  Front Psychol       Date:  2022-02-21

2.  Food Addiction in Eating Disorders: A Cluster Analysis Approach and Treatment Outcome.

Authors:  Lucero Munguía; Anahí Gaspar-Pérez; Susana Jiménez-Murcia; Roser Granero; Isabel Sánchez; Cristina Vintró-Alcaraz; Carlos Diéguez; Ashley N Gearhardt; Fernando Fernández-Aranda
Journal:  Nutrients       Date:  2022-03-04       Impact factor: 5.717

3.  A description of virtual skills workshops for supporters of loved ones with eating disorders: Indicators of benefit and acceptability, clinical reflections and consideration of neurodiversity.

Authors:  Amy Harrison; Rebecca Folk; Faye Proud; Jessica Webb; Oyenike Oyeleye; Danielle Clark Bryan; Joyce Webb; Hannah Webb; Wendy Whitaker; Namrata Dhopatkar; Janet Treasure
Journal:  Eur Eat Disord Rev       Date:  2022-07-21

4.  Lifetime Weight Course as a Phenotypic Marker of Severity and Therapeutic Response in Patients with Eating Disorders.

Authors:  Zaida Agüera; Cristina Vintró-Alcaraz; Isabel Baenas; Roser Granero; Isabel Sánchez; Jéssica Sánchez-González; José M Menchón; Susana Jiménez-Murcia; Janet Treasure; Fernando Fernández-Aranda
Journal:  Nutrients       Date:  2021-06-13       Impact factor: 5.717

5.  Neuropsychological Learning Deficits as Predictors of Treatment Outcome in Patients with Eating Disorders.

Authors:  Ignacio Lucas; Romina Miranda-Olivos; Giulia Testa; Roser Granero; Isabel Sánchez; Jessica Sánchez-González; Susana Jiménez-Murcia; Fernando Fernández-Aranda
Journal:  Nutrients       Date:  2021-06-23       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.